PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price

PROVECTUS BIOPHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price

PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price of $0.29 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice · last filed 2026-03-26

• PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, other share increase (decrease) in period, weighted average exercise price for fiscal 2025 was $0.29, a 0.00% change from fiscal 2024.
• PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, other share increase (decrease) in period, weighted average exercise price for fiscal 2024 was $0.29.